Mar. 19 at 4:48 PM
$GNTA financing terms seems favorable (at least kicking the dilution down the road):
"Total Bond: €20 million (
$21.9M), subscribed by ETB;
Maturity: three years, with mandatory conversion at maturity (March 2028);
Lock-up: two years following conversion (March 2030);
ETB equity in Genenta will be capped at 29%.
The maximum conversion price is
$17.64 per share based on an Independent Evaluation conducted by ETB’s Advisor on Genenta."
https://www.globenewswire.com/news-release/2025/03/19/3045505/0/en/Genenta-Announces-20-million-21-9M-Financing-To-Expand-Pipeline-As-Brain-Tumor-Trial-Is-Showing-Promising-Survival-Rates.html